Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. ERYTECH Pharma S.A.
  6. News
  7. Summary
    ERYP   FR0011471135

ERYTECH PHARMA S.A.

(ERYP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

JMP Securities Downgrades ERYTECH Pharma to Market Perform From Market Outperform

10/26/2021 | 06:06am EST


ę MT Newswires 2021
All news about ERYTECH PHARMA S.A.
11/17European ADRs Higher Wednesday as Credit Suisse, Barrick Gold Gain
MT
11/16European ADRs Mixed in Tuesday Morning Trading
MT
11/15ERYTECH Provides Business and Financial Update for the Third Quarter of 2021
AQ
11/15European ADRs Move Slightly Higher in Monday Trading
MT
11/15ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematolo..
GL
11/12European ADRs Move Lower in Friday Trading
MT
11/11GLOBAL MARKETS LIVE : Daimler, Delivery Hero, Foxconn, China Evergrande, Kraft Heinz...
11/09GLOBAL MARKETS LIVE : Euronext, AMC, PayPal, Roblox, UniCredit...
11/09ERYTECH to Present at the 12th Annual Jefferies Global London Healthcare Conference
AQ
11/05European ADRs Flat Friday as Travel Stocks Rise, Pharma Falls
MT
More news
Analyst Recommendations on ERYTECH PHARMA S.A.
More recommendations
Financials
Sales 2021 6,74 M 7,62 M 7,62 M
Net income 2021 -61,2 M -69,3 M -69,3 M
Net Debt 2021 16,1 M 18,2 M 18,2 M
P/E ratio 2021 -0,70x
Yield 2021 -
Capitalization 60,3 M 68,2 M 68,2 M
EV / Sales 2021 11,3x
EV / Sales 2022 6,62x
Nbr of Employees 196
Free-Float 67,5%
Chart ERYTECH PHARMA S.A.
Duration : Period :
ERYTECH Pharma S.A. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERYTECH PHARMA S.A.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Last Close Price 2,16 €
Average target price 4,30 €
Spread / Average Target 99,1%
EPS Revisions
Managers and Directors
Gil Beyen Chief Executive Officer & Director
Eric Soyer Chief Operating & Financial Officer
Jean-Paul Kress Chairman
Iman El-Hariry Chief Medical Officer
Stewart Craig Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
ERYTECH PHARMA S.A.-69.62%68
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678